NCT04037241: A trial that was reported late by Sorrento Therapeutics, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04037241 |
|---|---|
| Title | A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 1, 2021 |
| Completion date | Jan. 1, 2022 |
| Required reporting date | Jan. 1, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 4, 2022 |
| Days late | None |